DDX5 and cancer: DDX5 promotes cancer malignancy through multiple mechanisms, which include but may not be limited to (1) DDX5 interaction with β‐catenin to co‐activate the expression of cyclin D1 and c‐Myc32, 33, 53; (2) regulation of NF‐κB35; (3) involvement in the IncRNA, NEAT1‐mediated activation of Wnt/β‐catenin‐signalling46; (4) transcriptional activation of AKT31; and (5) coactivation of Stat3.37